Calcium channel blockers: What is their role in the treatment of hypertension in renal patients?

Journal of Nephrology

Volumn 9, Issue 6, 1996, Pages 286-290

  Pahor, Marco ^a   Psaty, Bruce M ^b   Furberg, Curt D ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

blockers; angiotensin converting enzyme inhibitors; calcium channel blockers; diuretics morbidity; hypertension; mortality; renal failure; surrogate outcomes

Indexed keywords

AMLODIPINE; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ISRADIPINE; LISINOPRIL; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; VERAPAMIL;

CLINICAL TRIAL; HUMAN; HYPERTENSION; KIDNEY DISEASE; REVIEW;

EID: 0030478673     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Hall WD. Renal issues in the management of hypertension. AmJ Hypertens 1993; 6: 245S-50.
2. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8.
3. Shulman NB, Ford CE, Hall D, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 1989; 13 (Suppl 1): I-80-93.
4. Salive ME, Jones CA, Corti MC, Pahor M, Agodoa LTY, Guralnik JM. Using mortality to set a reference range for serum creatinine level in older adults. Age Ageing (in press).
5. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-98.
6. Gordon RD. Calcium antagonists and gastrointestinal haemorrhage: the balancing act. Lancet 1996; 347: 1056.
7. Frohlich ED, Zanchetti A. Antihypertensive therapy: safety and efficacy of drugs and publications. Hypertension 1996; 27: 317-8.
8. Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. Eur Heart J 1996; 17: 1142-7.
9. Furberg CD, Psaty BM. Calcium antagonists: not appropriate as first-line antihypertensive agents. Am J Hypertens 1996; 9: 122-5.
10. Furberg CD, Psaty BM. Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives? J Am Geriatr Soc 1995; 43: 1309-10.
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62.
12. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
13. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992; 5: 423-30.
14. Kamper AL, Strandgaard S, Leyssac PP. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Nephrol Dial Transplant 1995; 10: 1182-8.
15. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S-92.
16. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of non-diabetic chronic renal disease. Arch Intern Med 1994; 154: 1185-202.
17. Ranieri G, Andriani A, Lamontanara G, De Cesaris R. Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther 1994; 56: 323-30.
18. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-80.
19. Bilo H, Kluitman E, van Ballegooie E, Potter van Loon BJ, Bakker K, Michels B, et al. Long term use of captopril or nifedipine in normotensive microalbuminuric patients with insulin-dependent diabetes mellitus. Diabetes Res 1993; 23: 115-22.
20. Schohn DC, Jahn HA, Maareck M. Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure. Drugs 1993; 46 (Suppl 2): 113-9.
21. Gilbert RE, Jerums J, Allen TJ, Hammond J, Cooper ME. Effect of different antihypertensive agents in normotensive microalbuminuric patients with IDDM and NIDDM (Abstract). Clin Nephrol 1994; 5: 377.
22. Schnack C, Capek M, Banyai M, Kautzky Willer A, Prager R, Schernthaner G. Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta Diabetol 1994; 31: 14-8.
23. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-72.
24. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
25. Pahor M, Guralnik JM, Corti C, Foley DJ, Carbonin PU, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-7.
26. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996; 276: 785-91.
27. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.
28. Wagenknecht LE, Furberg CD, Hammon JW, Legault C, Troost BT. Surgical bleeding: unexpected effect of a calcium antagonist. Br Med J 1995; 310: 776-7.
29. Kario K, Imiya M, Ohta Y, Shimada K. Gastrointestinal bleeding induced by amlodipine. J Hum Hypertens 1995; 9: 206-7.
30. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolyic therapy in the thrombolysis in myocardial infarction study. Thrombolysis in myocardial infarction, phase II, pilot and clinical trial. Circulation 1991, 83: 448-59.
31. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-9.
32. Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 1996; 9: 713-4.
33. Patel R, Lipper B, Schwartzbard A, Nelson C, O'Connor MA, Frishman W. Toxic effects of diltiazem in a patient with chronic renal failure. J Clin Pharmacol 1994; 34: 273-4.
34. Tomas S, Duaso E, Llibre J. Toxic effects of verapamil in chronic renal failure (letter). Med Clin Bare 1994; 102: 478.
35. Robles NR, Garcia Diaz MC, Fernandez Mora G, Sanchez Casado E. Poisoning by delayed-release verapamil in an uremic patient. Med Clin Barc 1992; 99: 741-2.
36. Rosansky SJ. Verapamil toxicity and renal failure. Arch Intern Med 1992; 152: 1925.
37. Pritza DR, Bierman MH, Hammeke MD. Acute toxic effects of sustained-release verapamil in chronic renal failure. Arch Intern Med 1991; 151: 2081-4.
38. AhmedJH, Grant AC, Rodger RSC, Murray GR, Elliott HR. Inhibitory effect of uremia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 1991; 32: 57-62.